Characteristics of 27 CML patients investigated for ex vivo levels of CD8+ T cells specific for the PR1 and PR2 epitopes
| Patient . | Disease . | Months posttransplantation . | % CD3+, CD8+, IFNγ+ cells . | |
|---|---|---|---|---|
| PR1 . | PR2 . | |||
| 1 | CR post-allo | 1 | 0.50 | 0.70 |
| 2 | CR post-allo | 4 | 0.20 | 0.40 |
| 3 | CR post-allo | 12.3 | 0.10 | 0.12 |
| 4 | CR post-allo | 12 | 0.10 | 0.10 |
| 5 | CR post-allo | 13 | 1.40 | 1.00 |
| 6 | CR post-allo | 13 | 1.90 | 1.60 |
| 7 | CR post-allo | 1 | 0.05 | 0.05 |
| 8 | CR post-allo | 4 | 0.01 | 0.01 |
| 9 | CR post-allo | 12 | 0.06 | 0.14 |
| 10 | CR post-allo | 6 | 0.07 | 0.13 |
| 11 | CR post-allo | 6 | 0.08 | 0.12 |
| 12 | CR post-allo | 6 | 0.02 | 0.02 |
| 13 | CR post-allo | 4 | 0.1 | 0.06 |
| 14 | CR post-CB transplantation | 11 | 0.60 | 0.30 |
| 15 | CR post-MUD | 7 | 0.00 | 0.10 |
| 16 | CR post-MUD | 22 | 0.10 | 0.00 |
| 17 | CR post-MUD | 23 | 0.10 | 0.20 |
| 18 | CR post-MUD | 9 | 0.50 | 0.60 |
| 19 | Relapsed on dasatinib | 192 | 0.10 | 0.20 |
| 20 | CCyR on dasatinib | NA | 0.02 | 0.02 |
| 21 | CCyR on imatinib | NA | 0.10 | 0.00 |
| 22 | CCyR on imatinib | NA | 0.00 | 0.00 |
| 23 | CCyR on nilotinib | NA | 0.10 | 0.10 |
| 24 | CR on dasatinib | NA | 0.00 | 0.00 |
| 25 | MCyR on IFN | NA | 0.00 | 0.00 |
| 26 | MCyR on nilotinib | NA | 0.00 | 0.10 |
| 27 | MCyR on nilotinib | NA | 0.02 | 0.12 |
| Patient . | Disease . | Months posttransplantation . | % CD3+, CD8+, IFNγ+ cells . | |
|---|---|---|---|---|
| PR1 . | PR2 . | |||
| 1 | CR post-allo | 1 | 0.50 | 0.70 |
| 2 | CR post-allo | 4 | 0.20 | 0.40 |
| 3 | CR post-allo | 12.3 | 0.10 | 0.12 |
| 4 | CR post-allo | 12 | 0.10 | 0.10 |
| 5 | CR post-allo | 13 | 1.40 | 1.00 |
| 6 | CR post-allo | 13 | 1.90 | 1.60 |
| 7 | CR post-allo | 1 | 0.05 | 0.05 |
| 8 | CR post-allo | 4 | 0.01 | 0.01 |
| 9 | CR post-allo | 12 | 0.06 | 0.14 |
| 10 | CR post-allo | 6 | 0.07 | 0.13 |
| 11 | CR post-allo | 6 | 0.08 | 0.12 |
| 12 | CR post-allo | 6 | 0.02 | 0.02 |
| 13 | CR post-allo | 4 | 0.1 | 0.06 |
| 14 | CR post-CB transplantation | 11 | 0.60 | 0.30 |
| 15 | CR post-MUD | 7 | 0.00 | 0.10 |
| 16 | CR post-MUD | 22 | 0.10 | 0.00 |
| 17 | CR post-MUD | 23 | 0.10 | 0.20 |
| 18 | CR post-MUD | 9 | 0.50 | 0.60 |
| 19 | Relapsed on dasatinib | 192 | 0.10 | 0.20 |
| 20 | CCyR on dasatinib | NA | 0.02 | 0.02 |
| 21 | CCyR on imatinib | NA | 0.10 | 0.00 |
| 22 | CCyR on imatinib | NA | 0.00 | 0.00 |
| 23 | CCyR on nilotinib | NA | 0.10 | 0.10 |
| 24 | CR on dasatinib | NA | 0.00 | 0.00 |
| 25 | MCyR on IFN | NA | 0.00 | 0.00 |
| 26 | MCyR on nilotinib | NA | 0.00 | 0.10 |
| 27 | MCyR on nilotinib | NA | 0.02 | 0.12 |
CML indicates chronic myeloid leukemia; PR, proteinase; CR, complete response; MCyR, major cytogenetic response, CCyR, complete cytogenetic response; allo, allogeneic stem cell transplantation; MUD, matched unrelated donor stem cell transplantation; CB, cord blood; and NA, not applicable.